Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 25;13(11):1941.
doi: 10.3390/genes13111941.

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics

Tasneem Farhad  1 , Keila Neves  1 , Patrick Arbuthnot  1 , Mohube Betty Maepa  1
Affiliations
Review

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics

Tasneem Farhad et al. Genes (Basel). .

Abstract

Adenoviral vaccines have been at the front line in the fight against pandemics caused by viral infections such as Ebola and the coronavirus disease 2019. This has revived an interest in developing these vectors as vaccines and therapies against other viruses of health importance such as hepatitis B virus (HBV). Current hepatitis B therapies are not curative; hence, chronic hepatitis B remains the major risk factor for development of liver disease and death in HBV-infected individuals. The ability to induce a robust immune response and high liver transduction efficiency makes adenoviral vectors attractive tools for anti-HBV vaccine and therapy development, respectively. This review describes recent developments in designing adenoviral-vector-based therapeutics and vaccines against HBV infection.

Keywords: adenovirus; gene therapy; hepatitis B virus; vaccine; viral vectors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Strategies to avoid immune responses to adenoviral vectors (AdVs). AdVs may elicit both innate and adaptive immune responses to vector proteins. Strategies to evade these immune responses include genetic modification to the viral capsid, use of less prevalent Ad serotypes, shielding the viral capsid by PEGylation, removal of viral sequences to generate gutless AdVs, and administering immunosuppressive drugs before vector injection (created with Biorender.com).
See this image and copyright information in PMC

References

    1. Alberts C.J., Clifford G.M., Georges D., Negro F., Lesi O.A., Hutin Y.J.-F., de Martel C. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review. Lancet Gastroenterol. Hepatol. 2022;7:724–735. doi: 10.1016/S2468-1253(22)00050-4. - DOI - PMC - PubMed
    1. Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J. Gastroenterol. 2021;27:6025–6038. doi: 10.3748/wjg.v27.i36.6025. - DOI - PMC - PubMed
    1. Iannacone M., Guidotti L.G. Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 2021;22:19–32. doi: 10.1038/s41577-021-00549-4. - DOI - PubMed
    1. Seto W.-K., Lo Y.-R., Pawlotsky J.-M., Yuen M.-F. Chronic hepatitis B virus infection. Lancet. 2018;392:2313–2324. doi: 10.1016/S0140-6736(18)31865-8. - DOI - PubMed
    1. McNaughton A., D’Arienzo V., Ansari M.A., Lumley S., Littlejohn M., Revill P., McKeating J., Matthews P.C. Insights from Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood. Gastroenterology. 2019;156:384–399. doi: 10.1053/j.gastro.2018.07.058. - DOI - PMC - PubMed

Publication types